title: High-dose nifuratel for simple and mixed aerobic vaginitis: A single-center prospective open-label cohort study.
abstract: OBJECTIVE
  The efficacy and safety of two nifuratel dosages for the treatment of aerobic vaginitis (AV) were compared.
  
  
  METHODS
  This was a prospective open-label cohort study of patients diagnosed and treated at the Tianjin Third Central Hospital between January 2012 and December 2013. The co-presence of bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), or/and trichomonal vaginitis (TV; mixed AV) was determined. Patients were randomized to nifuratel-500 (500 mg nifuratel, intravaginal, 10 days) or nifuratel-250 (250 mg nifuratel, intravaginal, 10 days), and followed-up for three to seven days after treatment completion. Primary and secondary outcomes were recovery rate and adverse events, respectively.
  
  
  RESULTS
  The study included 142 patients with AV. Age was not significantly different between the groups (n = 71 each), and disease distribution was identical: 29 (40.85%) simple AV and 42 (59.15%) mixed AV (AV + BV, 42.86 %; AV + VVC, 30.95%; AV + TV, 26.19%). In patients with simple AV, the recovery rate did not differ significantly between the nifuratel-500 (26/29, 89.66%) and nifuratel-250 (22/29, 75.86%) groups. In patients with mixed AV, recovery rates were significantly higher in the nifuratel-500 than in the nifuratel-250 group (AV + BV, 88.89% vs 50.00 %; AV + VVC, 76.92 % vs 30.77 %; AV + TV, 90.91 % vs 36.36%; all P < 0.05). Only one patient (nifuratel-500) reported an adverse event (mild anaphylactic reaction).
  
  
  CONCLUSIONS
  Nifuratel 500 mg showed good clinical efficacy for the treatment of AV, particularly mixed AV, and is superior to the 250 mg dosage in the treatment of mixed AV.
authors.affiliation: Department of Obstetrics and Gynecology, Tianjin Third Central Hospital, Tianjin, China. liangqian120tj@sina.com.
authors.forename: Qian
authors.initials: Q
authors.lastname: Liang
authors.affiliation: Department of Obstetrics and Gynecology, Tianjin Third Central Hospital, Tianjin, China.
authors.forename: Nan
authors.initials: N
authors.lastname: Li
authors.affiliation: Department of Obstetrics and Gynecology, Tianjin Third Central Hospital, Tianjin, China.
authors.forename: Shurong
authors.initials: S
authors.lastname: Song
authors.affiliation: Department of Obstetrics and Gynecology, Tianjin Third Central Hospital, Tianjin, China.
authors.forename: Aihua
authors.initials: A
authors.lastname: Zhang
authors.affiliation: Department of Obstetrics and Gynecology, Tianjin Third Central Hospital, Tianjin, China.
authors.forename: Ni
authors.initials: N
authors.lastname: Li
authors.affiliation: Department of Obstetrics and Gynecology, Tianjin Third Central Hospital, Tianjin, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Duan
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009545:Nifuratel / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D016896:Treatment Outcome; D014247:Trichomonas Vaginitis / Q000188:drug therapy; D014627:Vaginitis / Q000188:drug therapy*; D016585:Vaginosis, Bacterial / Q000188:drug therapy; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D009545:Nifuratel
keywords: aerobic vaginitis; bacterial vaginosis; candidal vaginitis; macmiror; nifuratel; trichomonas vaginitis